Roundup Glyphosate Lawsuits: Bayer's Settlements and the Science of Causation

$10 Billion in Settlements and a Science War That Isn't Over

When Bayer acquired Monsanto in 2018 for $63 billion, it inherited what would become the most expensive agricultural product litigation in history. Roundup — the world's most widely used herbicide — became the target of more than 125,000 lawsuits claiming its active ingredient, glyphosate, caused non-Hodgkin's lymphoma (NHL). By 2023, Bayer had paid or set aside more than $16 billion to settle claims, while simultaneously arguing in courts and before regulators that glyphosate is safe when used as directed. The contradiction at the heart of Roundup litigation — massive settlements alongside continued product sales — reveals how the civil justice system and regulatory science can reach radically different conclusions about the same compound.

Glyphosate is applied to more than 280 million acres of U.S. cropland annually. Understanding the legal and scientific debate matters for millions of farmers, homeowners, and agricultural workers.

The IARC Classification That Triggered the Litigation

The modern wave of Roundup litigation traces directly to a March 2015 decision by the International Agency for Research on Cancer (IARC), which classified glyphosate as "probably carcinogenic to humans" (Group 2A). This classification, based on limited evidence in humans and sufficient evidence in animals, triggered plaintiffs' law firms to recruit clients among agricultural workers and others with NHL diagnoses and significant Roundup exposure.

Critically, the IARC classification conflicted with regulatory assessments from the U.S. Environmental Protection Agency (EPA), the European Food Safety Authority (EFSA), and other agencies that concluded glyphosate was unlikely to be carcinogenic when used as directed. This scientific disagreement gave plaintiffs powerful ammunition — an IARC classification — while giving defendants credible regulatory cover.

Key Trial Verdicts

The pattern of large initial jury awards reduced substantially on appeal reflects judicial skepticism about punitive damage ratios while affirming underlying liability findings. The Ninth Circuit's 2021 ruling in Hardeman was particularly significant: it upheld the liability verdict and confirmed that federal law (FIFRA) did not preempt state failure-to-warn claims — a ruling that kept the litigation pipeline open.

The $10+ Billion Settlement Architecture

In June 2020, Bayer announced settlements totaling approximately $10.9 billion to resolve roughly 95,000 pending and future claims. The settlement structure included:

• Resolved claims: Approximately $8.8 billion for approximately 95,000 existing claims, with payment based on disease severity, exposure duration, and other factors.
• Future claims fund: Up to $1.25 billion set aside through a proposed class settlement for future NHL claimants — a component that courts ultimately rejected as inadequately structured.
• Science panel provision: A proposed independent science panel to evaluate future claims — also rejected by courts as an attempt to insulate Bayer from future jury awards.

Federal courts refused to approve the future claims component, leaving Bayer exposed to ongoing litigation from new plaintiffs diagnosed after the settlement date. By 2023, Bayer still faced tens of thousands of unresolved claims despite the massive payout.

The Causation Science: What Studies Show

The epidemiological evidence on glyphosate and NHL is genuinely contested among scientists:

• The Agricultural Health Study: A large, prospective cohort study of 89,000 farmers found no statistically significant association between glyphosate use and NHL overall, though one subtype (diffuse large B-cell lymphoma) showed a modest association.
• Zhang et al. (2019) meta-analysis: Found a 41% increased risk of NHL among the most highly exposed individuals — the key paper cited by plaintiffs' experts.
• IARC Monograph 112 (2015): Found "limited" evidence in humans but "sufficient" evidence in animals and classified glyphosate as Group 2A probable carcinogen.

Critics of the IARC classification note that it excluded unpublished industry studies with negative findings, while defenders argue that exclusion of industry-funded studies reduces bias. The dispute is unresolved in the scientific literature.

Bayer's Litigation Strategy and Future Outlook

Bayer has pursued legislative fixes, lobbying for federal legislation that would preempt state failure-to-warn claims and shield glyphosate products from litigation if they carry an EPA-approved label. As of 2024, no such legislation has passed. The company continues to sell Roundup while settling claims — a strategy that reflects the product's $4-5 billion annual revenue and the calculation that ongoing litigation costs, while enormous, are manageable against that revenue base.

This article is for informational purposes only and does not constitute legal advice.